Iovance Biotherapeutics Inc (IOVA):企業の財務・戦略的SWOT分析

◆英語タイトル:Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C3060
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥17,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥51,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Iovance Biotherapeutics Inc (IOVA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidate, LN-144 is an autologous, ready-to-infuse cell therapy. The product is an adoptive cell therapy using TIL technology and is being investigated in Phase II trials for treating patients with metastatic melanoma, recurrent and metastatic squamous cell carcinoma of the neck and head and recurrent and metastatic or persistent cervical cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

Iovance Biotherapeutics Inc Key Recent Developments

Aug 06,2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update
May 11,2018: RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics
May 10,2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
Mar 12,2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
Mar 01,2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Iovance Biotherapeutics Inc – Key Facts 6
Iovance Biotherapeutics Inc – Key Employees 7
Iovance Biotherapeutics Inc – Key Employee Biographies 8
Iovance Biotherapeutics Inc – Major Products and Services 9
Iovance Biotherapeutics Inc – History 10
Iovance Biotherapeutics Inc – Company Statement 11
Iovance Biotherapeutics Inc – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
Iovance Biotherapeutics Inc – Business Description 14
Iovance Biotherapeutics Inc – Corporate Strategy 15
Iovance Biotherapeutics Inc – SWOT Analysis 16
SWOT Analysis – Overview 16
Iovance Biotherapeutics Inc – Strengths 16
Iovance Biotherapeutics Inc – Weaknesses 17
Iovance Biotherapeutics Inc – Opportunities 18
Iovance Biotherapeutics Inc – Threats 19
Iovance Biotherapeutics Inc – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios – Interim Ratios 25
Financial Ratios – Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Iovance Biotherapeutics Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
Aug 06, 2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update 30
May 11, 2018: RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics 32
May 10, 2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 12, 2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 35
Mar 01, 2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors 37
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 38
Dec 13, 2017: BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics 39
Dec 13, 2017: Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017 40
Oct 31, 2017: Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results 41
Sep 07, 2017: Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center 44
Section 6 – Appendix 45
Methodology 45
Ratio Definitions 45
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Iovance Biotherapeutics Inc, Key Facts 6
Iovance Biotherapeutics Inc, Key Employees 7
Iovance Biotherapeutics Inc, Key Employee Biographies 8
Iovance Biotherapeutics Inc, Major Products and Services 9
Iovance Biotherapeutics Inc, History 10
Iovance Biotherapeutics Inc, Other Locations 12
Iovance Biotherapeutics Inc, Subsidiaries 12
Iovance Biotherapeutics Inc, Key Competitors 20
Iovance Biotherapeutics Inc, Ratios based on current share price 21
Iovance Biotherapeutics Inc, Annual Ratios 22
Iovance Biotherapeutics Inc, Annual Ratios (Cont...1) 23
Iovance Biotherapeutics Inc, Interim Ratios 25
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Iovance Biotherapeutics Inc, Recent Deals Summary 29
Currency Codes 45
Capital Market Ratios 45
Equity Ratios 46
Profitability Ratios 46
Cost Ratios 47
Liquidity Ratios 47
Leverage Ratios 48
Efficiency Ratios 48

List of Figures
Iovance Biotherapeutics Inc, Performance Chart (2013 - 2017) 24
Iovance Biotherapeutics Inc, Ratio Charts 26
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

★海外企業調査レポート[Iovance Biotherapeutics Inc (IOVA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ernst & Young Global Ltd:戦略・SWOT・企業財務分析
    Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report Summary Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Mtr Corporation Ltd
    Mtr Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Mtr Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Fortis Inc.:企業の戦略・SWOT・財務情報
    Fortis Inc. - Strategy, SWOT and Corporate Finance Report Summary Fortis Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Vision Ease, LP:医療機器:M&Aディール及び事業提携情報
    Summary Vision Ease, LP (Vision Ease), a subsidiary of HOYA Corp, is a manufacturer and marketer of ophthalmic lens. The company’s product portfolio includes photochromic lenses, progressives and multifocals, polarized lenses, and specialty lenses. It also provides venue lab services including lens …
  • Avitide Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avitide Inc (Avitide) strives to discover, manufacture and commercialize molecule-specific affinity purification solutions for biopharmaceutical industry. It offers affinity purification resins for developing bio-molecules including enzymes, non-antibody therapeutics, bispecific antibodies, …
  • Sernova Corp (SVA):医療機器:M&Aディール及び事業提携情報
    Summary Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company develops Cell Pouch System, an implantable medical device, which offers a natural organ-like …
  • Horama SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Horama SA (Horama) is a biotechnology company, which develops gene therapy products based on recombinant adeno-associated virus (rAAV) vectors for the treatment of rare ophthalmic diseases, including retinopathies and maculopathies. Its pipeline gene replacement products include HORA-RPE65, …
  • AF-Consult Switzerland AG:企業の戦略的SWOT分析
    AF-Consult Switzerland AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Amarillo Biosciences Inc (AMAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Amarillo Biosciences Inc (ABI) is a specialty biopharmaceutical company, which focuses on the development of biologics for the treatment of human and animal diseases. It develops innovative therapeutic candidates for the treatment of human disease indications such as influenza, hepatitis C, …
  • Siemens AG (SIE):石油・ガス:M&Aディール及び事業提携情報
    Summary Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution; oil and gas production and transportation; medical imagin …
  • MyoKardia Inc (MYOK):製薬・医療:M&Aディール及び事業提携情報
    Summary MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for rare cardiovascular diseases including heritable cardiomyopathies. The company's pipeline products include therapeutic programs for the treatment …
  • T&D Holdings, Inc.:企業の戦略・SWOT・財務分析
    T&D Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary T&D Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Protalex Inc (PRTX):企業の財務・戦略的SWOT分析
    Summary Protalex Inc (Protalex) is a biopharmaceutical company that develops drugs for the treatment of autoimmune and inflammatory diseases. The company offers treatment for a range of autoimmune diseases such as rheumatoid arthritis and immune thrombocytopenia. Its lead product candidate includes …
  • Polynt SpA:企業の戦略的SWOT分析
    Polynt SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • RATP Group:企業の戦略・SWOT・財務情報
    RATP Group - Strategy, SWOT and Corporate Finance Report Summary RATP Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Electric Power Development Co Ltd (9513):企業の財務・戦略的SWOT分析
    Electric Power Development Co Ltd (9513) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Huntsman Corp (HUN):企業の財務・戦略的SWOT分析
    Huntsman Corp (HUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Boar’s Head Provisions Co. Inc.:企業の戦略・SWOT・財務情報
    Boar’s Head Provisions Co. Inc. - Strategy, SWOT and Corporate Finance Report Summary Boar’s Head Provisions Co. Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Real Matters Inc (REAL):企業の財務・戦略的SWOT分析
    Real Matters Inc (REAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • PerkinElmer Inc (PKI)-医療機器分野:企業M&A・提携分析
    Summary PerkinElmer Inc (PerkinElmer) is a provider of detection, imaging, and informatics solutions and services to diagnostics, research, laboratory services, environmental, and industrial markets. The company’s product portfolio comprises lab products and services; imaging components; diagnostic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆